These laboratory-made antibodies are a best bet for a coronavirus treatment, but there won’t be enough

Experts have big hopes for these specialized drugs created by living cells. But they are expensive and hard to scale up, so even success will have limited impact on the virus.

View original article
Contributor: Carolyn Y. Johnson